Dr. Hong Liu’s efforts mainly dedicate to the research of medicinal chemistry and drug design and discovery. She is also focusing on the development of new organic synthetic methodologies, building focused combinatorial libraries, and the discovery and optimization of lead compounds for new drugs. Dr. Hong Liu has published 375 academic papers in peer-review journals, such as Science, Chemical Reviews, Angewandte Chemie International Edition, Journal of Medicinal Chemistry, Chemistry Communication, Green Chemistry, ACS catalysis, Organic Letters, etc. Dr. Liu wrote 12 books as chapter author as well and applied 213 patents. She has received many prizes such as the leading scientist in "Ten thousand Talent Program", Innovative Talent Promoting Program -Innovation Teams in Selected Areas of Priority, the 14th Science and Technology Award for Chinese Youth, The 6th National Excellent Scientific and Technical Workers, The 8th Chinese Young Women in Science Award, The National Science Fund for Distinguished Young Scholars, etc.

EDUCATION
09/01/1987-07/31/1991, B.S. in Medicinal Chemistry, China Pharmaceutical University
09/01/1993-07/31/1996, M.S in Medicinal Chemistry, China Pharmaceutical University
09/01/1996-07/31/1999, Ph.D. in Medicinal Chemistry, China Pharmaceutical University

WORK EXPERIENCE
09/01/1991-08/31/1993, Assistant Engineer, ShanDong Xinghua Pharmaceutical Company
08/01/1999-08/31/2001, Post-doctor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
02/01/2002-10/31/2002, Visiting Professor University of Texas Medical Branch
01/01/2005-10/31/2005, Visiting Professor University of Texas Medical Branch
09/01/2001-30/06/2006, Associate Professor and Master's supervisor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
01/07/2006-present, Professor and doctoral supervisor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Prof. Liu is the committee member of the Chinese Pharmaceutical Association, the Chinese Chemical Society, the Chinese Pharmacological Society, the shanghai Pharmaceutical Association, the Shanghai Chemical Industry and Engineering Society, the American Chemical Society, and is the Editorial Board Member of Journal of Medicinal Chemistry, Acta Pharmaceutica Sinica, Chinese Journal of medicinal chemistry, ACS Combinatorial Science, Organic Chemistry: Current Research, Current Microwave Chemistry and Current Green Chemistry.

The main Awards
09/2011, The 8th Outstanding Chinese Young Women in Science Award
11/2009, SA-SIBS 2009 Young Faculty Awards
12/2007, Third Prize of 1st WuXi PharmaTech Life Science and Chemistry Award
12/2007, Awardee of National Award for Natural Sciences, China Goverment
12/2004, Young Chemist Award from Chinese Chemical Society
07/2004, SERVIER Award for Young Medicinal Chemist from Chinese Pharmaceutical Association
12/2003, First Prize of Shanghai Sci-Tech Progress Award
07/2003, First prize of 9th Science and Technology Thesis for Youth of Shanghai

The honorary title
09/2012, Outstanding academic leaders of shanghai
11/2010, The Hundred Talents of Chinese Academy of Sciences
06/2010, China National Funds for Distinguished Young Scientists
04/2010, The 2th “Outstanding Young technological innovation” of the Shanghai Branch of Chinese Academy of Sciences
10/2009, Special Woman (San Ba) Award of China
05/2006, “Qimingxing” Extension Awards of Science and Technology for Youth of Shanghai
03/2004, Special Woman (San Ba) Award of Shanghai in China
05/2003, “Qimingxing” Awards of Science and Technology for Youth of Shanghai

1. To develop highly effectively synthetic methodologies to construct (chiral) heterocyclic compound libraries
2. To research and develop innovative drugs for some serious diseases
(1) Discovery of DPPIV inhibitor as an anti-diabetic drug
(2) Discovery of AChE inhibitor as an anti-Alzheimer’s disease drug
(3) Discovery of novel anti-BPH (Benign prostatic hyperplasia) drug
(4) Discovery and development of c-Met inhibitors as antineoplastic agents
(5) Discovery and development of CCR5 inhibitors as anti-HIV drug

1. The National Natural Science Foundation of China, The role of Sphingosine 1-phosphate on the metabolic abnormity of lipid in cancer and the exploration of the regulating mechanisms of critical condition of conversion from inflammation to cancer, Project Leader, 2013.01-2016.12
2. National S&T Major Projects, The preclinical R&D for drug candidate LJN of anti-diabetes, Project Leader, 2012.01-2015.12
3. Program of Shanghai Subject Chief Scientist, The construction of chiral privileged structure library and its application in the drug design and development, Project Leader, 2012.07-2014.06
4. The National Natural Science Foundation of China, Pharmaceutical chemistry, Project Leader, 2011.01-2014.12
5. F7 EU Framework Programme, Small-molecule inhibitor leads versus emerging and neglected RNA viruses, Project Leader of china, 2010.10-2014.09
6. China-EU Science and Technology Cooperation Project, Discovery of small molecule inhibitor for EV68 and EV71, Project Leader, 2011.12-2013.12
7. The 863 Hi-Tech Program of China, Research and development of JG3, DC06 and DC032, Project Leader, 2006.11-2010.12
8. The National Natural Science Foundation of China, Discovery of novel K+ channel blocker and study of its selectivity and biological function, Project Leader, 2008.1-2011.12

1.Wenhao Dai#, Bing Zhang#, Xia-Ming Jiang#, Haixia Su#, Jian Li, Yao Zhao, Xiong Xie, Zhenming Jin, Jingjing Peng, Fengjiang Liu, Chunpu Li, You Li, Fang Bai, Haofeng Wang, Xi Cheng, Xiaobo Cen, Shulei Hu, Xiuna Yang, Jiang Wang, Xiang Liu, Gengfu Xiao, Hualiang Jiang, Zihe Rao, Lei-Ke Zhang*, Yechun Xu*, Haitao Yang*, Hong Liu*. Structure-Based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease. Science. 2020, DOI: 10.1126/science.abb4489. 

2.Yichu Liu, Yibing Wang, Wenhao Dai, Wei Huang, Yingxia Li* and Hong Liu*. Palladium-Catalysed C(sp3)-H Glycosylation for Synthesis of C-Alkyl Glycoamino Acids. Angewandte Chemie International Edition. 2020, 59, 3491-3494. 

3.Xingjun Li#, Jiang Wang#, Xiong Xie, Wenhao Dai, Xu Han, Kaixian Chen* and Hong Liu*. Ir(III)-Catalyzed direct C-H functionalization of N-phenylacetamide with α-diazo quinones: a novel strategy for producing 2-hydroxy-2’amino-1,2’-biaryl scaffolds. Chemical Communications. 2020, 56, 3441-3444. 

4.Jingjing Peng, Chunpu Li, Mirzadavlat Khamrakulov, Jiang Wang* and Hong Liu*. Rhodium(III)-Catalyzed C-H Alkenylation: Access to Maleimide-Decorated Tryptophan and Tryptophan-Containing Peptides. Organic Letters. 2020, 22, 1535-1541. 

5.Xuewu Liang, Jie Zang, Xiaoyang Li, Shuai Tang, Min Huang, Meiyu Geng, C. James Chou, Chunpu Li, Yichun Cao, Wenfang Xu, Hong Liu,* and Yingjie Zhang*. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry. 2019, 62, 3898-3923. 

6.Yibing Wang, Hong Liu*. A Drug with Lipophilicity-dependent Potency Can Be Metabolically Stable: Discovery of a Potent and Selective Retinoic Acid Receptor-related Orphan Receptor C2 (RORC2) Inverse Agonist as an Orally Bioavailable Anti-inflammatory Agent. Journal of Medicinal Chemistry. 2018, 61, 10412-10414. 

7.Panfeng Peng, Huan Chen, Ya Zhu, Zhilong Wang, Jian Li, Rong-Hua Luo,Jiang Wang, Liang Chen, Liu-Meng Yang, Hualiang Jiang, Xin Xie,Beili Wu*, Yong-Tang Zheng*,and Hong Liu*.Structure -Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists. Journal of Medicinal Chemistry. 2018, 61, 9621-9636. 

8.Jianhui Zhou, Jian Li, Yazhou Li, Chenglin Wu, Guoxue He, Qiaolan Yang, Yu Zhou* and Hong Liu*.Direct Synthesis of 3-Acylindoles through Rhodium(III)-Catalyzed Annulation of N-Phenylamidines with α-Cl Ketones. Organic Letters. 2018, 20, 7645-7649. 

9.Feifei Fang, Chunmei Zhang, Chaofan Zhou, Yazhou Li, Yu Zhou,* and Hong Liu*. Rh(III)-Catalyzed C-H Activation of Benzoylacetonitriles and Tandem Cyclization with Diazo Compounds to Substituted Benzo[de]chromenes. Organic letters. 2018, 20, 1720-1724. 

10.Xiaowei Wu, Bao Wang, Shengbin Zhou, Yu Zhou,* and Hong Liu*. Ruthenium-Catalyzed Redox-Neutral [4+1] Annulation of Benzamides and Propargyl Alcohols via C-H Bond Activation. ACS catalysis. 2017, 7, 2494-2499. 

11.Wei Zhu, Hui Chen, Yulan Wang, Jiang Wang, Xia Peng, Xianjie Chen, Yinglei Gao, Yulong He, Jing Ai*, Meiyu Geng, Mingyue Zheng* and Hong Liu*. Design, Synthesis, and Pharmacological Evaluation of Novel Multi-substituted Pyridin-3-amine Derivatives as Multi-Targeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry. 2017, 60, 6018-6035. 

12.Xiaowei Wu, Bao Wang, Yu Zhou,and Hong Liu*. Propargyl alcohols as one-carbon synthons: redox-neutral Rh (III)-catalyzed C-H bond activation for the synthesis of isoindolinones bearing a quaternary carbon. Organic Letters. 2017, 19, 1294-1297. 

13.Yu Zhou, Jiang Wang, Zhanni Gu, Shuni Wang, Wei Zhu, Jose Luis Acena,* Vadim A. Soloshonok,* Kunisuke Izawa,* and Hong Liu*. Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II- III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. Chemical Reviews. 2016, 116, 422-518. 

14.Fei Zhao, Jing Li, Ying Chen, Yanxin Tian, Chenglin Wu, Yanan Xie, Yu Zhou, Jiang Wang, Xin Xie,* and Hong Liu*. Design, Synthesis, and Biological Evaluation of Indoline and Indole Derivatives as Potent and Selective α1A-Adrenoceptor Antagonists. Journal of Medicinal Chemistry. 2016, 59, 3826-3839. 

15.Diliang Guo, Jing Li, Henry Lin, Yu Zhou, Ying Chen, Fei Zhao, Haifeng Sun, Dan Zhang, Honglin Li, Brian K. Shoichet, Lei Shan, Weidong Zhang, Xin Xie,* Hualiang Jiang,* Hong Liu*. Design, Synthesis and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α1A-Adrenoceptor Antagonists. Journal of Medicinal Chemistry. 2016, 59, 9489-9502. 

16.Panfeng Peng, Jiang Wang, Hualiang Jiang,and Hong Liu*. Rhodium(III)-Catalyzed Site-Selective C-H Alkylation and Arylation of Pyridones Using Organoboron Reagents. Organic Letters. 2016, 18, 5376-5379. 

17.Yong Nian, Jiang Wang, Shengbin Zhou, Shuni Wang, Hiroki Moriwaki, Aki Kawashima, Vadim A. Soloshonok,* and Hong Liu*. Recyclable Ligands for the Non-Enzymatic Dynamic Kinetic Resolution of Challenging α-Amino Acids. Angewandte Chemie International Edition. 2015, 54, 12918–12922. 

18.Xiaowei Wu, Dengyou Zhang, Shengbin Zhou, Feng Gao and Hong Liu*. Site-specific indolation of proline-based peptides via copper(II)-catalyzed oxidative coupling of tertiary amine N-oxides. Chemical Communications. 2015, 51, 12571-12573. 

19.Dengyou Zhang, Feng Gao, Yong Nian, Yu Zhou, Hualiang Jiang, and Hong Liu*. Palladium-Catalyzed Picolinamide-Directed Coupling of C(sp2)-H and C(sp2)-H: a Straightforward Approach to Quinolinone and Pyridone Scaffolds. Chemical Communications. 2015, 51, 7509 -7511. 

20.Jiang Wang, María Sanchez-Rosello, Jose? Luis Acen?a, Carlos del Pozo, Alexander E. Sorochinsky, Santos Fustero*, Vadim A. Soloshonok,* Hong Liu*. Fluorine in Pharmaceutical Industry: Fluorinated Drugs Introduced to the Market in the Last Decade. Chemical Reviews. 2014,114, 2432-2506. 

21.Shengbin Zhou, Jiang Wang, Xia Chen, Jose Luis Acena ,Vadim A. Soloshonok,* and Hong Liu*. Chemical Kinetic Resolution of Unprotected b-Substituted-b-Amino Acids Using Recyclable Chiral Ligands. Angewandte Chemie International Edition. 2014, 53, 7883-7886. 

22.Ryosuke Takeda, Akie Kawamura, Aki Kawashima, Tatsunori Sato, Hiroki Moriwaki*, Kunisuke Izawa, Kenichi Akaji, Shuni Wang, Hong Liu,* Jose Luis Acena, and Vadim A. Soloshonok*. Chemical Dynamic Kinetic Resolution and S/R Interconversion of Unprotected a-Amino Acids. Angewandte Chemie International Edition. 2014,53, 12214-12217. 

23.Hao Cai, Yu Zhou, Dong Zhang, Jinyi Xu*, and Hong Liu*. A Mannich/Cyclization Cascade Process for the Asymmetric Synthesis of Spirocyclic Thioimida-zolidinexoindoles. Chemical Communications. 2014, 50, 14771-14774. 

24.Enguang Feng, Woo-Jin Shin, Xuelian Zhu, Jian Li, Deju Ye, Jiang Wang, Jian-Ping Zuo, Kyoung Tai No, Mingyue Zheng, Weiliang Zhu, * Wei Tang, * Baik-Lin Seong,* Hualiang Jiang, and Hong Liu*. Structure-Based Design, Synthesis of C-1 and C-4 modified analogs of zanamivir as neuraminidase inhibitors. Journal of Medicinal Chemistry. 2013, 56, 671-684. 

25.Shengtao Xu, Yu Zhou, Jinyi Xu*, Hualiang Jiang, and Hong Liu*. Gold-catalyzed Michael Addition/Intramolecular Annulation Cascade: an Effective Pathway for the Chemoselective- and Regioselective Synthesis of Tetracyclic Indole Derivatives in Water. Green Chemistry. 2013,15,718-726.